Business Wire

H.I.G. Capital Sells WERU Group to DOVISTA A/S

Share

H.I.G. Capital (“H.I.G.“), a leading global alternative investment firm with over €36 billion of equity capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its German portfolio company WERU Group (the “Company” or “WERU”) to DOVISTA A/S, a leading North European solution provider of vertical windows and exterior doors. The transaction is subject to clearance by the relevant antitrust authorities.

WERU, a leading manufacturer of PVC windows and doors in Germany, was acquired by H.I.G. in 2014, and subsequently acquired UNILUX, a leading manufacturer of wood-based windows and doors to expand its product portfolio. During H.I.G.’s ownership, WERU modernized the Company’s production facilities, launched new products, and implemented various digital innovations. Headquartered near Stuttgart in Germany, WERU sells its product offering via a broad network of more than 1,725 specialized retailers and has more than 1,100 employees across its three manufacturing sites in Germany.

Stefan Löbich, CEO of WERU, commented: “Over the past years, we worked very closely with H.I.G. and successfully implemented our jointly defined strategy. As a result, WERU is a major player within windows and doors in Germany today. Having an experienced, reliable, and financially strong partner such as H.I.G. on our side was extremely beneficial for the Company, and I thank H.I.G. for their continued support. Now I am truly excited to open a new chapter for WERU as part of DOVISTA Group.”

Allan Lindhard Jørgensen, CEO & President of DOVISTA A/S said: “Our two companies make a great fit. With the acquisition of WERU, we accelerate our plans to expand further and truly make all of Europe our home market. We add a notable German vertical windows and exterior doors brand to our existing brand portfolio and gain further traction in Germany which is a significant market for building a strong presence in Central Europe. We are delighted to welcome WERU and its employees to the DOVISTA family, and I very much look forward to working with the WERU team.”

Klaas Reineke, Managing Director at H.I.G., commented: “Working with Stefan Löbich and his team at WERU was a great pleasure for us. We worked closely with WERU management over the past years – with selected add-on acquisitions, continuous digitization efforts, and an even stronger customer focus, and as a result, WERU was able to strengthen its market position in Germany over the last years. We are convinced that WERU is very well positioned for further growth as part of DOVISTA, and we wish Stefan Löbich and his team every success for the future.”

About WERU

WERU is a leading German manufacturer of high-quality windows and external doors of residential buildings with a full range of frame materials and is headquartered in Rudersberg, Baden-Württemberg. WERU offers premium- and luxury products and WERU is perceived as a quality leader in the market. Among its competitors, WERU provides outstanding service quality, lead time, delivery reliability, and after sales support for specialist retailers. WERU has a renowned and distinguished brand, a "Made-in-Germany" reputation and a clear USP. WERU was awarded with "Deutsche Standards - Marke des Jahrhunderts" in 2019.

About DOVISTA

DOVISTA is a leading solution provider of vertical windows and exterior doors made from wood and wood/aluminium on the North European market. DOVISTA was founded in 2004 and is headquartered in Horsens, Denmark and today, more than 4,000 employees manufacture and distribute vertical windows and exterior doors to the core markets: Denmark, Sweden, Norway, the UK, and Ireland.

DOVISTA consists of nine distinctive brands with strong local roots that together represent about 600 years of experience within manufacturing of vertical windows and exterior doors: VELFAC, Rationel, SP Fönster, Traryd Fönster, Mockfjärds, O H Industri, Natre, Lian, and KRONE.

Every DOVISTA brand has its own market strategies, firmly anchored in its local markets, and closely connected to its customers. The brands also collaborate to create knowledge and synergies between the brands and strengthen the shared competences and qualities of the DOVISTA Group.

DOVISTA is part of the VKR Group and thereby, a sister company to VELUX. The VKR Group is owned by VKR Holding A/S, a limited company with a non-profit, charitable foundation as largest shareholder.

For more information, please refer to the DOVISTA website at www.DOVISTA.com.

About H.I.G. Capital

H.I.G. is a leading global alternative assets investment firm with over €36 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/value-added approach:

1. H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.

2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.

3. H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.

Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of €27 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.

* Based on total capital commitments managed by H.I.G. Capital and affiliates.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dr. Klaas Reineke
Managing Director
kreineke@higcapital.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s Analytics Earns #2 Overall Ranking in Chartis Research STORM505.8.2021 16:15:00 CEST | Press release

Moody’s Analytics is #2 in the inaugural Chartis Research STORM50 (Statistical Techniques, Optimization frameworks and Risk Models) ranking of the world’s leading providers of quantitative solutions for the financial industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210805005744/en/ Chartis’ STORM50 ranking measures the strength of solutions in quantitative modeling and software, assessing the level of innovation and the quality of the underlying computational infrastructure. The scoring is based on five criteria: breadth and coverage, impact, computational infrastructure, innovation, and strategy. In addition to the #2 ranking overall, Moody’s Analytics placed first in 14 of 55 categories, including Breadth & Coverage, Impact, Strategy, and Innovation, evidencing the depth of the company’s modeling expertise. “The inaugural Chartis Research STORM50 ranking highlights our ability to deliver an integrated view of risk

Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine5.8.2021 15:30:00 CEST | Press release

Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development. Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically-relevant markers combined with same slide-H&E analysis in precious tissue samples. Fluidigm is a leader in high-parameter imaging for the clinical translational research and clinical testing markets. It’s Imaging Mass Cytometry™ (IMC™) technology is designed for highly multiplexed targeted interrogation of tissue sections for 40 or more protein markers in one scan, with distinct non-overlapping signals from element-labeled antibodies detected simultaneous

Andersen Global Strengthens Puerto Rican Coverage with Tax and Advisory Firm5.8.2021 15:30:00 CEST | Press release

Andersen Global adds dimension to its platform in Puerto Rico with the addition of collaborating firm AFS CPA Group LLC (AFS), solidifying its presence in the country with tax and legal coverage. AFS provides tax and advisory services to clients including individuals and small and large businesses, serving a variety of industries such as legal, medical, food and restaurants, apparel, marketing, technology, non-profit and homeowners associations. The firm, established in 2000 by Founder and Managing Partner Antonio Sécola, is based in Gurabo and offers tax, financial, investment and cash management services as well as outsourcing and payroll functions. “As an Arthur Andersen alumnus, I look forward to rejoining the culture and working with like-minded individuals who are committed to serving clients best-in-class solutions,” Antonio said. “Our firm is dedicated to providing the highest quality service, and this collaboration further supplements our ability to deliver seamless solutions

Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine5.8.2021 15:22:00 CEST | Press release

Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine. The partnership expands Precision for Medicine’s ability to match patients who could benefit from life-saving therapies, especially those who could be a match for trials in oncology, rare and orphan diseases, including cell or gene therapy trials. Trialbee enables accurate and fast enrollment, improving the patient journey and helping to meet patient enrollment timelines. The Precision Site Network, which includes both academic and non-academic sites across North America, Europe, and Australia, can c

Loop Energy Enters Joint Market Development Agreement With Técnicas Reunidas to Accelerate the Commercialization of Hydrogen-Powered Vehicles5.8.2021 14:00:00 CEST | Press release

Loop Energy (TSX:LPEN), a developer and manufacturer of hydrogen fuel cell-based solutions, announces their joint market development agreement with Técnicas Reunidas (TR) – a global provider of services for investors in hydrogen infrastructure based in Madrid, Spain. Under this agreement, both parties will aim to secure future opportunities that require both TR’s hydrogen know-how and Loop Energy’s fuel cell technology. The initial scope of this joint market agreement focuses on providing hydrogen-based solutions to several key vertical markets: transport agencies, truck, transit and coach bus service fleets, materials handling, warehouse and port logistics including drayage, urban delivery services and stationary power applications. With the assistance of TR’s on-site production and supply equipment, creating hydrogen both via water electrolysis and steam reforming of natural gas, biogas or bioethanol, Loop will be able to provide more convenient and cost-effective hydrogen solutions

Moody's to Acquire RMS, Leader in Climate & Natural Disaster Risk5.8.2021 13:18:00 CEST | Press release

Moody's Corporation (NYSE: MCO) and RMS announced today that they have entered into a definitive agreement for Moody’s to acquire RMS, a leading global provider of climate and natural disaster risk modeling and analytics, for approximately $2.0 billion from Daily Mail and General Trust plc (LON: DMGT). The acquisition will immediately increase Moody’s insurance data and analytics business to nearly $500 million in revenue and will accelerate the development of the Company’s global integrated risk capabilities to address the next generation of risk assessment. With over 400 risk models covering 120 countries, RMS is the world’s leading provider of climate and natural disaster risk modeling serving the global property and casualty (P&C) insurance and reinsurance industries. For the fiscal year ending September 30, 2021, RMS is expected to generate revenue of approximately $320 million1 and adjusted operating income of approximately $55 million1. "Today’s leaders face a complex, interlink

Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO ® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks5.8.2021 13:00:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced the publication of the final results from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE) designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO® (lanadelumab) 300mg every two weeks for up to 2.5 years. The study results show that preventative treatment with TAKHZYRO markedly reduced the frequency of hereditary angioedema (HAE) attacks in patients 12 years of age and older who received treatment for a mean duration of almost 2.5 years (29.6 months; 8.2 standard deviation).1 The data were published online this month in the journal Allergy. Secondary endpoints of the study showed the mean (min;max) HAE attack rate observed in the study population (N=209) was reduced by 87.4 percent (-100; 852.8) overall versus baseline, and attacks requiring acute treatment (N=106) were reduced by 93.4 percent (-100; -52.8).1 Reductions were

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom